A PHASE I STUDY OF PRALSETINIB IN PATIENTS WITH RET ALTERED SOLID TUMOR
Phase 1
- Conditions
- RET altered solid tumor
- Registration Number
- JPRN-jRCT2031210144
- Lead Sponsor
- Yanagitani Noriko
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Histologically or cytologically documented solid tumors
ECOG PS of Grade 0 or 1
RET alteration has been identified
Advanced or recurrent cancer for which standard therapy is ineffective or for which no standard therapy exists
Exclusion Criteria
Other than RET alteration, known major driver mutations have been identified
There has been a history of administration of other selective RET inhibitors
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method